Conference Correspondent

Omadacycline is a new intravenous/oral antibiotic for patients presenting in the emergency department with acute bacterial skin and soft tissue infections.
The randomized, controlled Omadacycline in Acute Skin Structure Infections Study (OASIS)-2 study comparing omadacycline and linezolid for the treatment of adults with an acute bacterial skin and skin structure infection (ABSSSI) that is known or suspected to result from a gram-positive pathogen enrolled 735 patients, with 368 and 367 patients in each group, respectively.
Investigators evaluated the in vitro activity of omadacycline, a novel aminomethylcycline antibiotic, against a collection of clinical isolates resistant to other available tetracyclines.
A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
The findings of the current study suggest that patients with rheumatoid arthritis (RA) who achieve low disease activity with subcutaneous tocilizumab plus methotrexate (MTX) may potentially discontinue MTX and maintain disease control with tocilizumab monotherapy.
This analysis showed that patients with active, moderate-to-severe rheumatoid arthritis (RA) treated with sarilumab plus methotrexate (MTX) achieved longer duration of response versus those treated with placebo plus MTX, regardless of the definition of response used.
This post-hoc analysis showed that ongoing sarilumab treatment on the MOBILITY and TARGET studies resulted in achievement of remission or low disease activity increased through week 24 in patients with rheumatoid arthritis (RA) and inadequate response to methotrexate and inadequate response to, or intolerance of, tumor necrosis factor inhibitors.
In the open-label extension phase of the phase 3 MONARCH trial, patients switching from monotherapy with adalimumab 40 mg to open-label monotherapy with sarilumab 200 mg every 2 weeks demonstrated improvements in rheumatoid arthritis (RA) signs and symptoms and physical function that were numerically similar to patients who were initially randomized to sarilumab 200 mg every 2 weeks.
The findings of this study showed that patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) reported clinically meaningful improvements in patient-reported outcomes (PROs) with all 3 treatment regimens (tofacitinib monotherapy, tofacitinib plus MTX, and adalimumab plus MTX). PROs were comparable between tofacitinib plus MTX and adalimumab plus MTX therapies, with combination therapy numerically higher than tofacitinib monotherapy.
Post-hoc pooled analyses of the MOBILITY and TARGET trials showed that sarilumab plus disease-modifying antirheumatic drug (DMARD) treatment in diabetic patients with rheumatoid arthritis (RA) led to reductions in glycosylated hemoglobin (HbA1c) and lowered fasting glucose levels; reductions in HbA1c were also achieved by nondiabetic patients with RA.
Page 1 of 8
Results 1 - 10 of 80
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME